My Pitch: "Contrave, the company's already-FDA-approved-in-the-U.S. obesity drug, will be approved for sale in the EU, pending a positive approval decision in the EMA committee meeting that was held on Mon. March 16, 2015.

Estimates put the post-approval SP at $11-$15, with analyst upgrades to follow !"

My Pitch: "Barchart.com http://j.mp/k9b8Qn via*Orexigen Therapeutics (OREX)3.25 +0.42 (+14.84%) Wed, Jun 1st, 2011 CHART* NEWS@VOL ALERT BOUNCE! biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity"

My Pitch: "I switched to OREX from ARNA due to the Light study results and OREX only has 116 million shares outstanding with 90% investment managers owning this. And in my opinion after some research they have the best drug. Will be determined.

Started position at $5.31, 5.46 and 5.72"

My Pitch: "In for Contrave CV benefit "

My Pitch: "BULLISH"

My Pitch: ".4906"

My Pitch: "......"

My Pitch: "Gych"

My Pitch: "VVUS play"

My Pitch: "If Orexigen makes a good international move to sell Contrave around the globe, then we might see some healthy results from $OREX's stock price."

My Pitch: "550"